+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating ART6043, an oral anti-cancer drug, alone or combined with the PARP inhibitor olaparib, in patients with advanced or metastatic solid tumors. The study focuses on cancers with DNA repair defects and includes patients with specific genetic mutations like germline BRCA in advanced breast cancer. The trial aims to assess safety, tolerability, pharmacokinetics, and preliminary effectiveness of ART6043. The study has two parts Part A includes dose escalation of ART6043 alone Part A1 and in combination with olaparib Part A2 for advanced cancers with DNA damage response gene defects. Part B is a dose-expansion phase comparing ART6043 plus olaparib against olaparib alone in patients with HER2-negative advanced breast cancer and germline BRCA mutations. Treatments are administered in 21-day cycles, and patients may continue therapy as long as clinical benefit is observed or until progression or unacceptable toxicity. Participants will undergo regular assessments including monitoring for dose limiting toxicities during the first treatment cycle and progression-free survival over up to 3.7 years. Evaluations include adverse events, tumor response, changes in tumor size and cancer markers, pharmacokinetics, and overall survival. Safety is monitored throughout, with follow-up visits after treatment discontinuation. The total study duration may extend until disease progression or other stopping criteria are met.

Age: 18Years +All GendersPhase 1Phase 2
27 locations